A 69-year-old Caucasian man was referred to Baylor University Medical Center at Dallas with resting lower-extremity pain and a nonhealing sore above his right ankle (Rutherford chronic ischemia stage 5 of 6) after having failed multiple attempts at revascularization. He was enrolled in a clinical research trial using adult autologous stem cells for treatment of critical limb ischemia. Autologous stem cells from the patient's pelvic bone marrow were harvested, concentrated in the operating room, and reinjected into the lower leg along the vasculature below the level of complete occlusion of the popliteal artery and around the ulcer. After 3 months, the patient had significant improvement in his ankle brachial index, which increased from 0.10 to 0.40 (normal 0.9-1.01), and early healing. After 12 months, the ulcer was fully healed. Healing of the sore has persisted for 3 years.
I
n approximately 30% of cases of critical limb ischemia (CLI), revascularization will fail and amputation will be required (1). To avoid amputation, a patient was enrolled in a novel study in which the use of autologous bone marrow-derived stem cells facilitated the healing of his ischemic leg wound and led to resolution of his ischemic rest pain.
CASE PRESENTATION
A 69-year-old Caucasian man with long-standing peripheral arterial disease (PAD) was referred for evaluation of lowerextremity revascularization for limb salvage or possible amputation. He smoked 40 cigarettes daily for 56 years until 2009. He also had a history of hyperlipidemia, hypertension, chronic obstructive pulmonary disease, and heavy ethanol intake until 2008.
Th e patient's fi rst procedure for PAD occurred in 2002, when he underwent traditional bilateral femoral-popliteal bypass surgery using saphenous vein grafts. Th e right femoral to popliteal graft failed in 2008, 6 years after its construction, and a second graft surgery was performed using cadaveric vein from his external iliac to his popliteal artery. Th is graft occluded acutely but was successfully reopened with thrombectomy and placement of a patch graft to the distal anastomosis during the same hospitalization.
By January 2009, the second graft had also completely occluded and a third right graft surgery was performed using cadaveric vein, this time from the external iliac to the posterior tibial artery at the ankle. Unfortunately, this graft became infected and had to be removed a month later. A saphenous vein harvested from the left leg was then placed to the right ankle but could not prevent the wound dehiscence that occurred above the right ankle. Four months after wound debridement, the patient continued to have rest pain and the wound. Angiography showed complete occlusion of the right superfi cial femoral artery, right popliteal artery, and all right leg grafts.
Because of his history of acute graft thrombosis requiring surgical thrombectomy, he was treated with warfarin therapy for over a year to keep his grafts open. Th is had to be discontinued, however, after an episode of gastrointestinal bleeding. During this 7-year period the patient underwent eight additional procedures, including fi ve angiography procedures with four angioplasties and three procedures for PAD on the contralateral leg. He thus had had over 11 hospitalizations and procedures for PAD in the 7 years before stem cell treatment.
At the time of his referral, amputation had been recommended to him, as he had had claudication for 7 years, resting foot pain for 6 months, and a nonhealing ulcer above his ankle for 4 months. When it was determined that the patient had no additional revascularization options for limb salvage, he was enrolled in Harvest Technologies' "Feasibility Study of the Safety and Activity of Autologous Bone Marrow Aspirate Concentration (BMAC) for the Treatment of Critical Limb Ischemia Due to Peripheral Arterial Occlusive Disease" (2) . His right ankle brachial index at the time of referral was 0.1, with a toe brachial index of 0. His PAD was consistent with Rutherford chronic ischemia stage 5 (rest pain with ulceration).
Th e patient was taken to the operating room where he was randomized into the study by two nonblinded research staff . All other research staff , operating room staff , and the vascular surgery team were excused from the operating room during this time to maintain the blind. For subjects randomized to receive placebo, a mixture of peripheral blood and saline was made that appeared identical to the prepared stem cell concentrate. In addition, small amounts of bone marrow were collected from each hip so all patients remained blinded to their treatment. Because this patient was randomized to receive stem cells, the hematologist harvested, under anesthesia, 240 mL of bone marrow from both iliac crests.
After preparation of the stem cell mixture, blinded staff returned to the operating room and treated the patient with 40 one-mL injections into his right leg below the knee. Sonographic guidance was used to inject the concentrate along blood vessels beyond the level of the complete vascular occlusion, which in this case was the right popliteal artery, as well as around the edges of the wound.
After 3 months, the patient had signifi cant improvement in his ankle brachial index, which increased from 0.10 to 0.40 (normal 0.9-1.01) (Figure 1) . By 12 months, the wound had completely healed and has remained healed through 3 years of follow up (Figure 2) . Th e patient continues to have claudication with signifi cant exertion, but this does not interfere with his usual daily activities, which include baling hay and other rigorous activities in the management of his farm. Since the stem cell implantation procedure, he has had no hospitalizations or operative procedures.
DISCUSSION
Common manifestations of severe CLI are rest pain and tissue loss in the aff ected extremity (1, 3) . Current therapies for improving extremity blood fl ow include endovascular and surgical revascularization. To generate wound healing in an ischemic limb, blood fl ow must be restored to the matrix of the wound via blood vessel formation (4-6). Unfortunately, this cannot occur in adults with critical blockages in arteries, and patients with CLI often develop secondary wounds (6) . Th e goal of treatment for CLI-originated wounds is to induce "therapeutic angiogenesis" (6) .
Th is patient developed a wound that could not be healed in the absence of adequate blood fl ow. He was enrolled in a pilot trial using bone marrow-derived stem cells, which were collected, processed, and immediately returned to the patient in the same procedure (2, 7) . In this procedure, a nonspecifi c mononuclear cell mix was implanted with minimal time spent outside the patient's body. Because the goal was to encourage growth of collateral vascular circulation, the cells were injected along the blood vessels below the critical vascular obstruction, which in this patient occurred at the knee. While it should take some time for any repair process to be eff ective, this patient had clear evidence of improvement by days 32 and 53 postprocedure. Th e sore completely healed by 12 months postprocedure and has remained healed for 3 years after stem cell treatment.
Stem cells are believed to work via a number of mechanisms. Th e original belief was that adult autologous stem cells can turn into, and replace, any damaged adult cells (8) . More recent literature, however, suggests that stem cells may function as repair "traffi c cops," directing both circulating and local cells to areas of tissue damage and stimulating their repair functions (9) . Because using body resources to repair tissues is a costly process, activated stem cells appear to have a built-in time-limited function, encouraging local repair between 3 and 12 months. Th is was demonstrated by the fact that improvement in the ankle brachial index made no further gains after 3 months. At that time, the stem cells may have either evolved into adult quiescent cells or undergone apoptosis and autodestructed.
Th is clinical research trial demonstrated a statistically signifi cant 50% reduction in the need for amputation in patients with CLI and tissue loss (7) . Th is patient continues to have some exercise-induced claudication, but he is able to perform the functions required of his daily life. Other stem cell clinical research trials for PAD have shown similar increases in ankle brachial indices and an overall decrease in rest pain (3) . Th e fi rst of these trials was the TACT study, which was published in 2002 in Japan (10) . Th is was the same year this patient's disease was fi rst diagnosed and treated.
Th ese early clinical research trials using stem cells to treat advanced tissue disease only enroll patients with end-stage disease for whom no other therapies are available. Th is is appropriate because this is the only patient population for whom the risk-to-benefi t ratio is favorably balanced, given our early state of understanding. Interestingly, most stem cell clinical research studies have had excellent early safety profi les, as adult autologous stem cells are well tolerated. Potential risks are due predominantly to manipulation of the cells and the therapeutic procedure performed to deliver the cells to the tissues.
Th e full potential for the use of stem cells for replacement or healing of damaged tissue has yet to be realized. Due to the time-limited activity of stem cells, patients treated with bone marrowderived stem cells might benefi t further from a repeat treatment. While the routine use of stem cell therapies has not arrived, this one patient experienced relief of pain, wound healing, and prevention of amputation. 
